People · Operator
Named in public records as an officer, director or promoter · active 2018–2026 · Biotechnology, Pharmaceuticals, Healthtech, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RayzeBio, Inc. | — | Biotechnology | Series D+ | $396.4M | $3.4B | 2020 |
| Harmony Biosciences II, Inc. | — | Pharmaceuticals | Series D+ | $345.0M | $1.8B | 2018 |
| Swift Health Systems Inc. | — | Healthtech | Series D+ | $172.6M | $2.0B | 2019 |
| Neurogastrx, Inc. | — | Biotechnology | Series C | $80.0M | $1.7B | 2021 |
| Marea Therapeutics, Inc. | — | Biotechnology | Series C | $65.4M | $595.9M | 2024 |
| Akero Therapeutics, Inc. | — | Pharma | Series C | $45.5M | $1.6B | 2018 |
| Caldera Therapeutics, Inc. | — | Biotechnology | Series B | $37.5M | $139.2M | 2026 |
Aaron Royston at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aaron Royston on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Maha Katabi | 2 | 6 |
| Aaron Kantoff | 2 | 6 |
| Antonio Gracias | 1 | 15 |
| Kevin Bitterman | 1 | 15 |
| Jack Nielsen | 1 | 13 |
| Jerel Davis | 1 | 13 |
| Chris Garabedian | 1 | 8 |
| Klaus Veitinger | 1 | 6 |
| Patrick Morris | 1 | 6 |
| Peter Moldt | 1 | 6 |
| Jeffrey Aronin | 1 | 6 |
| Martin Edwards | 1 | 5 |
| Mark Iwicki | 1 | 4 |
| Darien Parhad | 1 | 4 |
| Juan Sabater | 1 | 4 |
| JOHN JACOBS | 1 | 3 |
| Mary Tagliaferri | 1 | 3 |
| Michael Gladstone | 1 | 3 |
| Michelle Doig | 1 | 3 |
| Andrew Goldberg | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.